89bio, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| 89bio, Inc. | ETNB - NASDAQ |
$15.00-$17.00 | $16.00 | $20.00 | 5.3 million | 11/11/2019 |
| BofA Merrill Lynch, SVB Leerink, RBC Capital | ||||||
Co-Manager(s): Oppenheimer | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-10-11 Terms Added 2019-10-28 S-1MEF 2019-11-08 | ||||||
89bio, Inc. Quote & Chart - Click for current quote - ETNB
IPO Boutique aggregates information on public companies and private companies, such as "ETNB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About 89bio, Inc. (adapted from 89bio, Inc. prospectus):
They are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ETNB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.